127 related articles for article (PubMed ID: 16299254)
1. Phosphatidylinositol 3-kinase mediates angiogenesis and vascular permeability associated with ovarian carcinoma.
Hu L; Hofmann J; Jaffe RB
Clin Cancer Res; 2005 Nov; 11(22):8208-12. PubMed ID: 16299254
[TBL] [Abstract][Full Text] [Related]
2. In vivo and in vitro ovarian carcinoma growth inhibition by a phosphatidylinositol 3-kinase inhibitor (LY294002).
Hu L; Zaloudek C; Mills GB; Gray J; Jaffe RB
Clin Cancer Res; 2000 Mar; 6(3):880-6. PubMed ID: 10741711
[TBL] [Abstract][Full Text] [Related]
3. Phosphatidylinositol 3-kinase inhibitors are a triple threat to ovarian cancer.
Parsons R
Clin Cancer Res; 2005 Nov; 11(22):7965-6. PubMed ID: 16299225
[No Abstract] [Full Text] [Related]
4. Inhibition of phosphatidylinositol 3'-kinase increases efficacy of paclitaxel in in vitro and in vivo ovarian cancer models.
Hu L; Hofmann J; Lu Y; Mills GB; Jaffe RB
Cancer Res; 2002 Feb; 62(4):1087-92. PubMed ID: 11861387
[TBL] [Abstract][Full Text] [Related]
5. The oncogene phosphatidylinositol 3'-kinase catalytic subunit alpha promotes angiogenesis via vascular endothelial growth factor in ovarian carcinoma.
Zhang L; Yang N; Katsaros D; Huang W; Park JW; Fracchioli S; Vezzani C; Rigault de la Longrais IA; Yao W; Rubin SC; Coukos G
Cancer Res; 2003 Jul; 63(14):4225-31. PubMed ID: 12874030
[TBL] [Abstract][Full Text] [Related]
6. Albendazole: a potent inhibitor of vascular endothelial growth factor and malignant ascites formation in OVCAR-3 tumor-bearing nude mice.
Pourgholami MH; Yan Cai Z; Lu Y; Wang L; Morris DL
Clin Cancer Res; 2006 Mar; 12(6):1928-35. PubMed ID: 16551879
[TBL] [Abstract][Full Text] [Related]
7. [Expression of phosphatidylinositol-3 kinase in epithelial ovarian carcinoma].
Zhang PN; Sun H
Zhonghua Fu Chan Ke Za Zhi; 2007 Mar; 42(3):196-200. PubMed ID: 17537308
[TBL] [Abstract][Full Text] [Related]
8. Vascular endothelial growth factor-trap decreases tumor burden, inhibits ascites, and causes dramatic vascular remodeling in an ovarian cancer model.
Byrne AT; Ross L; Holash J; Nakanishi M; Hu L; Hofmann JI; Yancopoulos GD; Jaffe RB
Clin Cancer Res; 2003 Nov; 9(15):5721-8. PubMed ID: 14654557
[TBL] [Abstract][Full Text] [Related]
9. [Inhibitory effect of tirapazamine combined with phosphatidylinositol 3-kinase inhibitor LY294002 to ovarian cancer cells].
Ren Y; Zha X; Zhang GN
Zhonghua Yi Xue Za Zhi; 2007 May; 87(17):1204-6. PubMed ID: 17686243
[TBL] [Abstract][Full Text] [Related]
10. Effects of the phosphatidylinositol 3-kinase inhibitor in a mouse model of retinal neovascularization.
Yu WZ; Zou H; Li XX; Yan Z; Dong JQ
Ophthalmic Res; 2008; 40(1):19-25. PubMed ID: 18025837
[TBL] [Abstract][Full Text] [Related]
11. PI3K/PTEN/AKT signaling regulates prostate tumor angiogenesis.
Fang J; Ding M; Yang L; Liu LZ; Jiang BH
Cell Signal; 2007 Dec; 19(12):2487-97. PubMed ID: 17826033
[TBL] [Abstract][Full Text] [Related]
12. Vascular endothelial growth factor trap combined with paclitaxel strikingly inhibits tumor and ascites, prolonging survival in a human ovarian cancer model.
Hu L; Hofmann J; Holash J; Yancopoulos GD; Sood AK; Jaffe RB
Clin Cancer Res; 2005 Oct; 11(19 Pt 1):6966-71. PubMed ID: 16203789
[TBL] [Abstract][Full Text] [Related]
13. 4-Hydroxy estradiol but not 2-hydroxy estradiol induces expression of hypoxia-inducible factor 1alpha and vascular endothelial growth factor A through phosphatidylinositol 3-kinase/Akt/FRAP pathway in OVCAR-3 and A2780-CP70 human ovarian carcinoma cells.
Gao N; Nester RA; Sarkar MA
Toxicol Appl Pharmacol; 2004 Apr; 196(1):124-35. PubMed ID: 15050414
[TBL] [Abstract][Full Text] [Related]
14. Functional expression of the angiotensin II type 1 receptor in human ovarian carcinoma cells and its blockade therapy resulting in suppression of tumor invasion, angiogenesis, and peritoneal dissemination.
Suganuma T; Ino K; Shibata K; Kajiyama H; Nagasaka T; Mizutani S; Kikkawa F
Clin Cancer Res; 2005 Apr; 11(7):2686-94. PubMed ID: 15814650
[TBL] [Abstract][Full Text] [Related]
15. Vascular endothelial growth factor immunoneutralization plus Paclitaxel markedly reduces tumor burden and ascites in athymic mouse model of ovarian cancer.
Hu L; Hofmann J; Zaloudek C; Ferrara N; Hamilton T; Jaffe RB
Am J Pathol; 2002 Nov; 161(5):1917-24. PubMed ID: 12414537
[TBL] [Abstract][Full Text] [Related]
16. [Avastin combined with cisplan inhibits malignant ascites production in nude mice bearing transplanted ovary carcinoma with high VEGF expression].
Cai YJ; Zheng DY; Luo RC; Chen JZ; Li AM; Xi JL; Ding XM
Nan Fang Yi Ke Da Xue Xue Bao; 2007 May; 27(5):647-9. PubMed ID: 17545079
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of malignant ascites and growth of human ovarian carcinoma by oral administration of a potent inhibitor of the vascular endothelial growth factor receptor tyrosine kinases.
Xu L; Yoneda J; Herrera C; Wood J; Killion JJ; Fidler IJ
Int J Oncol; 2000 Mar; 16(3):445-54. PubMed ID: 10675474
[TBL] [Abstract][Full Text] [Related]
18. Soluble FLT-1 expression suppresses carcinomatous ascites in nude mice bearing ovarian cancer.
Hasumi Y; Mizukami H; Urabe M; Kohno T; Takeuchi K; Kume A; Momoeda M; Yoshikawa H; Tsuruo T; Shibuya M; Taketani Y; Ozawa K
Cancer Res; 2002 Apr; 62(7):2019-23. PubMed ID: 11929819
[TBL] [Abstract][Full Text] [Related]
19. Antivascular therapy for orthotopic human ovarian carcinoma through blockade of the vascular endothelial growth factor and epidermal growth factor receptors.
Thaker PH; Yazici S; Nilsson MB; Yokoi K; Tsan RZ; He J; Kim SJ; Fidler IJ; Sood AK
Clin Cancer Res; 2005 Jul; 11(13):4923-33. PubMed ID: 16000591
[TBL] [Abstract][Full Text] [Related]
20. Significance of Akt phosphorylation on tumor growth and vascular endothelial growth factor expression in human gastric carcinoma.
Kobayashi I; Semba S; Matsuda Y; Kuroda Y; Yokozaki H
Pathobiology; 2006; 73(1):8-17. PubMed ID: 16785763
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
